Q&A

How Fulcrum Therapeutics Protects Its Data

Source: Egnyte

By James Allgood

Security Lock

Chris Moxham, Ph.D., is the Chief Scientific Officer at Fulcrum Therapeutics, an innovative biotech addressing the causes of genetically defined disease. By developing treatments that address the root cause of disease, Fulcrum goes a step further than creating therapies that just manage symptoms and develops treatments that alter the genetic expression of disease, enabling life-changing outcomes.

Like many in the Life Sciences, the challenges that Fulcrum face are similar to those across the drug-development industry. The outsourcing of specialized tasks is increasing, and the data that is generated from these efforts is massive, often unstructured, and scattered across repositories. Maintaining GxP compliance, creating a secure environment for collaboration, and ensuring there is a single source of truth are becoming more and more of a hassle.

Read how Fulcrum has turned to technology to help automate many of these processes in order to streamline collaboration with third-parties and the organization of data into a single repository.

VIEW THE Q&A!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Clinical Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: